Lifecore Biomedical, a fully integrated injectables CDMO, signed two new CDMO manufacturing service agreements with a United States-based pharmaceutical company.

Terms of Agreements

One agreement is a commercial site transfer enabling Lifecore to manufacture a currently marketed product previously produced by another CDMO. The product is new to Lifecore, which is planning technical transfer services including process performance qualification batches at commercial scale.

Lifecore will initiate commercial manufacture upon satisfactory completion of all regulatory requirements.

In the other agreement, Lifecore will begin to manufacture a commercial product it currently produces, in a second delivery system. This expansion of services concerns a treatment for ophthalmic-related diseases.

The second delivery modality referred to in this portion of the agreement is already manufactured in Europe.

Lifecore did not name the company in a press release, but said it has a pre-existing partnership with this biopharmaceutical customer. Product names have also been withheld at this time.

Lifecore Growing Its Partnerships

CEO Paul Josephs contextualized the agreement’s timing during the Drug, Chemical & Associated Technologies Association (DCAT) Week. DCAT Week is running from March 23–26, 2026, in New York City.

Josephs said Lifecore agreed to another commercial site transfer earlier in the week.

“The fourth [agreement] in the last five months is a testament to Lifecore’s successful new commercial strategy,” Josephs said. Such transfers “present a higher probability of approval than earlier stage development programs. We believe this high-value program may start generating meaningful commercial revenue in 2028.”

According to Josephs, the latest agreement also reflects Lifecore’s growing position as a partner-of-choice.

“We are honored to have been selected again by this valued customer,” Josephs said. “We are also very excited by the momentum in our growing late-stage pipeline and remain highly focused on leveraging this success.”